Turns out, Rudy Tanzi didn't see much of a story about a hidden link between Enbrel and Alzheimer's either
The Washington Post managed to whip up the quickest industry consensus I’ve ever seen that one of its reporters was purveying overblown nonsense with a story that Pfizer was sitting on data suggesting that Enbrel could be an effective treatment for Alzheimer’s.
In covering that bit of anti-Big Pharma fantasy — there are lots of reasons to go after pharma, but this piece was ludicrous — I noted comments in the story from some prominent people in the field criticizing Pfizer for not publishing the data. I singled out Rudy Tanzi at Harvard and then applied some added criticism for the things he’s done to hype — in my opinion — highly questionable assumptions. You can see it in the link.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.